Logo image of IRTC

IRHYTHM TECHNOLOGIES INC (IRTC) Stock Fundamental Analysis

NASDAQ:IRTC - Nasdaq - US4500561067 - Common Stock - Currency: USD

136.24  +0.48 (+0.35%)

After market: 136.24 0 (0%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to IRTC. IRTC was compared to 187 industry peers in the Health Care Equipment & Supplies industry. While IRTC seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, IRTC is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

In the past year IRTC has reported negative net income.
IRTC had a positive operating cash flow in the past year.
IRTC had negative earnings in each of the past 5 years.
IRTC had negative operating cash flow in 4 of the past 5 years.
IRTC Yearly Net Income VS EBIT VS OCF VS FCFIRTC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M -80M -100M

1.2 Ratios

With a decent Return On Assets value of -10.62%, IRTC is doing good in the industry, outperforming 60.96% of the companies in the same industry.
The Return On Equity of IRTC (-113.45%) is worse than 65.24% of its industry peers.
Industry RankSector Rank
ROA -10.62%
ROE -113.45%
ROIC N/A
ROA(3y)-22.19%
ROA(5y)-19.41%
ROE(3y)-77.27%
ROE(5y)-56.18%
ROIC(3y)N/A
ROIC(5y)N/A
IRTC Yearly ROA, ROE, ROICIRTC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 400

1.3 Margins

With a decent Gross Margin value of 69.39%, IRTC is doing good in the industry, outperforming 79.14% of the companies in the same industry.
In the last couple of years the Gross Margin of IRTC has declined.
IRTC does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 69.39%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.34%
GM growth 5Y-1.83%
IRTC Yearly Profit, Operating, Gross MarginsIRTC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60 -60

5

2. Health

2.1 Basic Checks

IRTC does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for IRTC has been increased compared to 1 year ago.
Compared to 5 years ago, IRTC has more shares outstanding
IRTC has a worse debt/assets ratio than last year.
IRTC Yearly Shares OutstandingIRTC Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
IRTC Yearly Total Debt VS Total AssetsIRTC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

An Altman-Z score of 3.03 indicates that IRTC is not in any danger for bankruptcy at the moment.
IRTC has a better Altman-Z score (3.03) than 69.52% of its industry peers.
A Debt/Equity ratio of 7.47 is on the high side and indicates that IRTC has dependencies on debt financing.
Looking at the Debt to Equity ratio, with a value of 7.47, IRTC is doing worse than 91.98% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 7.47
Debt/FCF N/A
Altman-Z 3.03
ROIC/WACCN/A
WACC8.53%
IRTC Yearly LT Debt VS Equity VS FCFIRTC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

IRTC has a Current Ratio of 5.71. This indicates that IRTC is financially healthy and has no problem in meeting its short term obligations.
IRTC's Current ratio of 5.71 is amongst the best of the industry. IRTC outperforms 80.75% of its industry peers.
IRTC has a Quick Ratio of 5.58. This indicates that IRTC is financially healthy and has no problem in meeting its short term obligations.
IRTC has a better Quick ratio (5.58) than 83.42% of its industry peers.
Industry RankSector Rank
Current Ratio 5.71
Quick Ratio 5.58
IRTC Yearly Current Assets VS Current LiabilitesIRTC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 29.57% over the past year.
IRTC shows a strong growth in Revenue. In the last year, the Revenue has grown by 20.55%.
IRTC shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 22.49% yearly.
EPS 1Y (TTM)29.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%22.76%
Revenue 1Y (TTM)20.55%
Revenue growth 3Y22.39%
Revenue growth 5Y22.49%
Sales Q2Q%20.27%

3.2 Future

The Earnings Per Share is expected to grow by 23.39% on average over the next years. This is a very strong growth
Based on estimates for the next years, IRTC will show a quite strong growth in Revenue. The Revenue will grow by 17.85% on average per year.
EPS Next Y42.17%
EPS Next 2Y36.04%
EPS Next 3Y29.69%
EPS Next 5Y23.39%
Revenue Next Year18.86%
Revenue Next 2Y17.83%
Revenue Next 3Y17.46%
Revenue Next 5Y17.85%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
IRTC Yearly Revenue VS EstimatesIRTC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 200M 400M 600M 800M 1B
IRTC Yearly EPS VS EstimatesIRTC Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 2 -2

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for IRTC. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IRTC. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IRTC Price Earnings VS Forward Price EarningsIRTC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 -100 -200

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IRTC Per share dataIRTC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

A more expensive valuation may be justified as IRTC's earnings are expected to grow with 29.69% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.04%
EPS Next 3Y29.69%

0

5. Dividend

5.1 Amount

IRTC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

IRHYTHM TECHNOLOGIES INC

NASDAQ:IRTC (7/18/2025, 8:00:02 PM)

After market: 136.24 0 (0%)

136.24

+0.48 (+0.35%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-01 2025-05-01/amc
Earnings (Next)07-31 2025-07-31/amc
Inst Owners112.97%
Inst Owner Change-0.11%
Ins Owners1.04%
Ins Owner Change2.01%
Market Cap4.35B
Analysts86.32
Price Target148.64 (9.1%)
Short Float %8.38%
Short Ratio4.76
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)54.27%
Min EPS beat(2)4.68%
Max EPS beat(2)103.85%
EPS beat(4)3
Avg EPS beat(4)6.42%
Min EPS beat(4)-115.67%
Max EPS beat(4)103.85%
EPS beat(8)4
Avg EPS beat(8)-15.15%
EPS beat(12)6
Avg EPS beat(12)-8.91%
EPS beat(16)10
Avg EPS beat(16)-0.35%
Revenue beat(2)2
Avg Revenue beat(2)1.71%
Min Revenue beat(2)1.42%
Max Revenue beat(2)2%
Revenue beat(4)2
Avg Revenue beat(4)0.32%
Min Revenue beat(4)-1.42%
Max Revenue beat(4)2%
Revenue beat(8)4
Avg Revenue beat(8)0.32%
Revenue beat(12)6
Avg Revenue beat(12)0.04%
Revenue beat(16)10
Avg Revenue beat(16)1.07%
PT rev (1m)4.09%
PT rev (3m)10.48%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0.86%
EPS NY rev (1m)0%
EPS NY rev (3m)-6.93%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.87%
Revenue NY rev (1m)0%
Revenue NY rev (3m)2.08%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7.03
P/FCF N/A
P/OCF 91.53
P/B 50.19
P/tB 50.7
EV/EBITDA N/A
EPS(TTM)-2.81
EYN/A
EPS(NY)-0.46
Fwd EYN/A
FCF(TTM)-0.03
FCFYN/A
OCF(TTM)1.49
OCFY1.09%
SpS19.37
BVpS2.71
TBVpS2.69
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -10.62%
ROE -113.45%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 69.39%
FCFM N/A
ROA(3y)-22.19%
ROA(5y)-19.41%
ROE(3y)-77.27%
ROE(5y)-56.18%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.34%
GM growth 5Y-1.83%
F-Score6
Asset Turnover0.67
Health
Industry RankSector Rank
Debt/Equity 7.47
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 233.65%
Cap/Sales 7.85%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.71
Quick Ratio 5.58
Altman-Z 3.03
F-Score6
WACC8.53%
ROIC/WACCN/A
Cap/Depr(3y)235.33%
Cap/Depr(5y)237.52%
Cap/Sales(3y)7.91%
Cap/Sales(5y)7.51%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)29.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%22.76%
EPS Next Y42.17%
EPS Next 2Y36.04%
EPS Next 3Y29.69%
EPS Next 5Y23.39%
Revenue 1Y (TTM)20.55%
Revenue growth 3Y22.39%
Revenue growth 5Y22.49%
Sales Q2Q%20.27%
Revenue Next Year18.86%
Revenue Next 2Y17.83%
Revenue Next 3Y17.46%
Revenue Next 5Y17.85%
EBIT growth 1Y39.77%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year147.59%
EBIT Next 3Y48.61%
EBIT Next 5Y33.49%
FCF growth 1Y97.78%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y419.62%
OCF growth 3YN/A
OCF growth 5YN/A